Physician profile
Nitin Jindal
NPI 1942863329
$1,250.67
in general payments reported to CMS, 2019-2025
22 companies · $627 in 2025
The $627 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $624 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211 · Education: $39.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,210.83 |
| Education | $39.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $358.53 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $187.44 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $108.62 | 2024-2025 | Rexulti |
| Abbvie INC. | $93.92 | 2024 | |
| Exact Sciences Corporation | $92.12 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $72.89 | 2024-2025 | |
| Lundbeck LLC | $45.67 | 2024-2025 | Rexulti |
| Medtronic, INC. | $37.45 | 2025 | Minimed 780g |
| Collegium Pharmaceutical, INC. | $30.74 | 2024 | Belbuca |
| Insulet Corporation | $27.57 | 2025 | Omnipod |
| Glaxosmithkline, LLC. | $20.25 | 2025 | Shingrix, Arexvy |
| Kyowa Kirin, INC. | $20.04 | 2025 | |
| Abbott Laboratories | $19.84 | 2025 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $18.25 | 2025 | Voquezna |
| Astellas Pharma US INC | $16.33 | 2024 | Veozah |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $15.46 | 2024 | Sublocade |
| Pfizer INC. | $15.26 | 2024 | |
| Merck Sharp & Dohme LLC | $15.17 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $14.95 | 2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.55 | 2024 | |
| Ibsa Pharma INC. | $13.35 | 2024 | Tirosint, Licart |
| Idorsia Pharmaceuticals US INC | $13.27 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Jindal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.